 |
19 Diseases |  |
0 Trials |
|
0 Trials |  |
13 News |  |
- LymphoCide Y-90 (epratuzumab Y-90) / Immunomedics, lucatumumab (CHIR 12.12) / Novartis, Xoma
Aberrant expression of β5t in the periphery induces a self-reactive T-cell response (Board Number: P176) - Apr 25, 2020 - Abstract #IMMUNOLOGY2020IMMUNOLOGY_70;
These results demonstrate that the aberrant peripheral expression of β5t disrupts the maintenance of a naïve pool of CD8+ T cells and induces autoreactive T-cell responses. The self-peptides generated by β5t are required to confine in the thymus to avoid autoimmunity in the peripheral tissues, and self-peptides mimicking β5t-producing peptides in the periphery may cause the failure of immunological regulation and tolerance.
- | Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Journal: Emerging immune targets for the treatment of multiple myeloma. (Pubmed Central) - May 15, 2019
No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab...A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.
- | lucatumumab (CHIR 12.12) / Novartis, Xoma
Phase classification: Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 12, 2018
P1, N=33, Completed, Sponsor: Novartis Pharmaceuticals
The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising. Phase classification: P2 --> P1
- |||| lucatumumab (CHIR 12.12) / Novartis, Xoma
Trial completion, Metastases: Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies (clinicaltrials.gov) - Jan 20, 2014
P1/2, N=111, Completed, Sponsor: Novartis Pharmaceuticals
Phase classification: P2 --> P1 Active, not recruiting --> Completed
- ||| lucatumumab (CHIR 12.12) / Novartis, Xoma
Enrollment change, Metastases: Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies (clinicaltrials.gov) - May 14, 2013
P1/2, N=111, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=149 --> 111
- lucatumumab (CHIR 12.12) / Novartis, Xoma
Trial completion, Combination therapy: LIFT: Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma (clinicaltrials.gov) - Nov 25, 2012
P1, N=1, Completed, Sponsor: Novartis Pharmaceuticals
N=149 --> 111 Terminated --> Completed
- | lucatumumab (CHIR 12.12) / Novartis, Xoma
Trial completion: Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 17, 2012
P2, N=33, Completed, Sponsor: Novartis Pharmaceuticals
Terminated --> Completed Terminated --> Completed
- lucatumumab (CHIR 12.12) / Novartis, Xoma
Enrollment change, Combination therapy: LIFT: Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma (clinicaltrials.gov) - Jul 29, 2012
P1, N=1, Completed, Sponsor: Novartis Pharmaceuticals
Terminated --> Completed N=50 --> 1